Back to Search Start Over

Using 5-Nitroimidazole Derivatives against Neglected Tropical Protozoan Diseases: Systematic Review

Authors :
Micheel M. Vichi-Ramírez
Edgar López-López
Catalina Soriano-Correa
Carolina Barrientos-Salcedo
Source :
Future Pharmacology, Vol 4, Iss 1, Pp 222-255 (2024)
Publication Year :
2024
Publisher :
MDPI AG, 2024.

Abstract

Neglected tropical diseases (NTDs) are a significant global health problem. Additionally, anti-protozoan treatments are toxic, and their therapeutic regimens require prolonged treatment times and high concentrations of the drugs. Additionally, multi-resistant protozoan strains represent an important global emergency that must be addressed. For these reasons, global efforts are being made to identify new drug candidates that are capable of combating these kinds of diseases. This systematic review shows that 5-nitroimidazole derivatives have been successfully used against neglected tropical protozoan diseases (NTPDs), with a specific focus on three diseases: malaria, leishmaniasis, and human trypanosomiasis. Some nitroimidazole derivatives have been repurposed, and an important group of new drugs is available for the treatment of NTPDs. Finally, we address 5-nitroimidazoles using chemoinformatics and medicinal chemistry tools to describe the most recent and promising 5-nitroimidazole derivatives associated with anti-protozoal activity using their published in vitro and in vivo data. We show that 5-nitroimidazoles offer a broader spectrum of activity against a variety of protozoal pathogens. More importantly, these compounds demonstrate a significantly reduced systemic toxicity compared to other nitroimidazoles. This makes them a more favorable option in the treatment of protozoal infections, particularly in scenarios where the patient’s tolerance to drug side effects is a critical concern.

Details

Language :
English
ISSN :
26739879
Volume :
4
Issue :
1
Database :
Directory of Open Access Journals
Journal :
Future Pharmacology
Publication Type :
Academic Journal
Accession number :
edsdoj.44af7443e614540916aac2a9d8771b6
Document Type :
article
Full Text :
https://doi.org/10.3390/futurepharmacol4010015